160 related articles for article (PubMed ID: 23506410)
1. Fatal interstitial lung disease induced by rituximab-containing chemotherapy, treatment with TNF-α antagonist and cytokine profiling: a case-report and review of the literature.
Wu Y; Jia Y; Xu J; Shuai X; Wu Y
J Clin Pharm Ther; 2013 Jun; 38(3):249-53. PubMed ID: 23506410
[TBL] [Abstract][Full Text] [Related]
2. Rituximab-induced interstitial lung disease: case report and literature review.
Zayen A; Rais H; Rifi H; Ouarda M; Afrit M; Cherif A; Mezline A
Pharmacology; 2011; 87(5-6):318-20. PubMed ID: 21613805
[TBL] [Abstract][Full Text] [Related]
3. Involvement of NLRP3 inflammasome in rituximab-induced interstitial lung disease: a case report.
Kong H; Wang Y; Zeng X; Zhu Q; Xie W; Dai S
J Clin Pharm Ther; 2014 Dec; 39(6):691-4. PubMed ID: 25131433
[TBL] [Abstract][Full Text] [Related]
4. Rituximab-induced interstitial lung disease.
Wagner SA; Mehta AC; Laber DA
Am J Hematol; 2007 Oct; 82(10):916-9. PubMed ID: 17597477
[TBL] [Abstract][Full Text] [Related]
5. Low absolute lymphocyte count and addition of rituximab confer high risk for interstitial pneumonia in patients with diffuse large B-cell lymphoma.
Huang YC; Liu CJ; Liu CY; Pai JT; Hong YC; Teng HW; Hsiao LT; Chao TC; Gau JP; Liu JH; Hsu HC; Chiou TJ; Chen PM; Yu YB; Tzeng CH
Ann Hematol; 2011 Oct; 90(10):1145-51. PubMed ID: 21647583
[TBL] [Abstract][Full Text] [Related]
6. TNF-α antagonist may not be suitable for severe rituximab-induced interstitial lung disease.
Tan J; Ni X
J Clin Pharm Ther; 2015 Jun; 40(3):249-50. PubMed ID: 25809984
[TBL] [Abstract][Full Text] [Related]
7. Rituximab-induced subacute interstitial pneumonitis: a case report and review of literature.
Subramanian M; Manjunath R; Kilara N; Mohan Rao KN
J Cancer Res Ther; 2010; 6(3):344-6. PubMed ID: 21119272
[TBL] [Abstract][Full Text] [Related]
8. Increased levels of tumor necrosis factor-α involved in rituximab-related acute pulmonary fibrosis in diffuse large B-cell lymphoma.
Zhang X; Guo X; Pan J
Am J Clin Pathol; 2015 May; 143(5):725-7. PubMed ID: 25873507
[TBL] [Abstract][Full Text] [Related]
9. Pathogenic study of anti-CD20 infusion-related severe refractory shock in diffuse large B-cell lymphoma.
Gutiérrez A; Rodríguez J; Martínez J; Amezaga R; Ramos R; Galmes B; Bea MD; Ferrer J; Pons J; Sampol A; Morey M; Duran MA; Raurich J; Besalduch J
Leuk Lymphoma; 2006 Jan; 47(1):111-5. PubMed ID: 16321834
[TBL] [Abstract][Full Text] [Related]
10. Interstitial lung disease induced or exacerbated by TNF-targeted therapies: analysis of 122 cases.
Perez-Alvarez R; Perez-de-Lis M; Diaz-Lagares C; Pego-Reigosa JM; Retamozo S; Bove A; Brito-Zeron P; Bosch X; Ramos-Casals M
Semin Arthritis Rheum; 2011 Oct; 41(2):256-64. PubMed ID: 21277618
[TBL] [Abstract][Full Text] [Related]
11. [Rituximab-induced interstitial lung disease].
Fernández Casares M; Espósito G; González A; Segovia J; Galperín Mde L; Del Valle E
Medicina (B Aires); 2013; 73(4):343-5. PubMed ID: 23924535
[TBL] [Abstract][Full Text] [Related]
12. Lung involvement and drug-induced lung disease in patients with rheumatoid arthritis.
Atzeni F; Boiardi L; Sallì S; Benucci M; Sarzi-Puttini P
Expert Rev Clin Immunol; 2013 Jul; 9(7):649-57. PubMed ID: 23899235
[TBL] [Abstract][Full Text] [Related]
13. Non-infectious pulmonary toxicity of rituximab: a systematic review.
Hadjinicolaou AV; Nisar MK; Parfrey H; Chilvers ER; Ostör AJ
Rheumatology (Oxford); 2012 Apr; 51(4):653-62. PubMed ID: 22157468
[TBL] [Abstract][Full Text] [Related]
14. [Interstitial pneumonia connected with rituximab therapy--case report].
Wyrostkiewicz D; Skorupa W; Barańska I; Kuś J
Pneumonol Alergol Pol; 2013; 81(5):453-9. PubMed ID: 23996885
[TBL] [Abstract][Full Text] [Related]
15. [Interstitial pneumonitis as a side effect of rituximab].
Kemming JL; van Zeeland RE; Ullmann EF; Mattijssen EJ
Ned Tijdschr Geneeskd; 2009; 153():A526. PubMed ID: 19785875
[TBL] [Abstract][Full Text] [Related]
16. Eternacept for the treatment of patients with rheumatoid arthritis and concurrent interstitial lung disease.
Horai Y; Miyamura T; Shimada K; Takahama S; Minami R; Yamamoto M; Suematsu E
J Clin Pharm Ther; 2012 Feb; 37(1):117-21. PubMed ID: 21128990
[TBL] [Abstract][Full Text] [Related]
17. Strikingly high false positivity of surveillance FDG-PET/CT scanning among patients with diffuse large cell lymphoma in the rituximab era.
Avivi I; Zilberlicht A; Dann EJ; Leiba R; Faibish T; Rowe JM; Bar-Shalom R
Am J Hematol; 2013 May; 88(5):400-5. PubMed ID: 23423884
[TBL] [Abstract][Full Text] [Related]
18. Retrospective analysis of primary gastric diffuse large B cell lymphoma in the rituximab era: a multicenter study of 95 patients in Japan.
Tanaka T; Shimada K; Yamamoto K; Hirooka Y; Niwa Y; Sugiura I; Kitamura K; Kosugi H; Kinoshita T; Goto H; Nakamura S
Ann Hematol; 2012 Mar; 91(3):383-90. PubMed ID: 21822617
[TBL] [Abstract][Full Text] [Related]
19. Clinical outcome in diffuse large B-cell lymphoma with hepatitis C virus infection in the rituximab era: a single center experience.
Nishikawa H; Tsudo M; Osaki Y
Oncol Rep; 2012 Sep; 28(3):835-40. PubMed ID: 22736295
[TBL] [Abstract][Full Text] [Related]
20. [Acute lung injury in a patient with concurrent diffuse large B-cell lymphoma and myelodysplastic syndrome].
Tokuyama T; Muta T; Yasunaga M; Nakanishi H; Ueda Y; Fujisaki T
Gan To Kagaku Ryoho; 2011 Oct; 38(10):1733-7. PubMed ID: 21996978
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
